Question 1

What is Geographic Atrophy?

Accepted Answer

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterized by the progressive loss of retinal cells in the macula, leading to central vision loss.

Question 2

What is the Geographic Atrophy market size in the United States?

Accepted Answer

The Geographic Atrophy market in the United States is estimated to be ~$1 billion.

Question 3

Which therapies are leading the geographic atrophy market?

Accepted Answer

Immune response-targeting agents have emerged as the most advanced area of clinical research for Geographic Atrophy, marking a significant milestone as the first and only drug class to enter the market to date. The FDA approvals of IZERVAY (avacincaptad pegol) and SYFOVRE (pegcetacoplan) represent groundbreaking developments.

Question 4

What are the key Geographic Atrophy companies?

Accepted Answer

Key companies involved in the development and commercialization of treatments for geographic atrophy (GA) are Apellis Pharmaceuticals, Roche (Genentech), Iveric Bio, Regeneron Pharmaceuticals, Novartis.